NCT05709106

A Prospective Real World Study of Rimegepant in the Treatment of Migraine

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 173 (actual)
• Sponsor: Ruijin-Hainan Hospital Shanghai Jiao Tong University School Of Medicine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this observational study is to test the effectiveness and safety of Rimegepant in the treatment of migraine patients in real world. The main questions it aims to answer are: * \[question 1\] the effectiveness and safety of Rimegepant in the acute treatment of migraine * \[question 2\] the effectiveness and safety of Rimegepant in the long-term treatment of migraine. 1. Participants will be asked to take Rimegepant when they need to treat or prevent a migraine attack. 2. Participants will be asked to record the efficacy data at 0.5, 1, 2, 24, 48h post dose and report any AE to evaluate the effectiveness and safety of Rimegepant in the acute treatment of migraine 3. Participants will be asked to track monthly migraine days and the use of Rimegepant, finish 2 PROs during the follow-ups, report any AE to evaluate the effectiveness and safety of Rimegepant in the long-term treatment of migraine.

Conditions

• Migraine

Interventions

Type	Name	Description
DRUG	Rimegepant 75 MG	Migraine patients would take Rimegepant 75 MG to treat or prevent a migraine attack and patients would be followed up for 1 year

Timeline

• Start date: 2023-01-11
• Primary completion: 2024-10-06
• Completion: 2025-04-09
• First posted: 2023-02-01
• Last updated: 2026-02-05

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study